Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters

Gherghe, Mirela; Mutuleanu, Mario-Demian; Suta, Tatiana Lucia; Micu, Liliana; Stanciu, Adina Elena; Ionescu, Sinziana-Octavia; Cirimbei, Ciprian; Paun, Diana Loreta; Jercan, Andreea; Badelita, Sorina Nicoleta; Coriu, Daniel

doi:10.3390/diagnostics15040482

Open AccessArticle

Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters

by

Mirela Gherghe

^1,2

,

Mario-Demian Mutuleanu

^1,2,*

,

Tatiana Lucia Suta

^2,*

,

Liliana Micu

²,

Adina Elena Stanciu

³

,

Sinziana-Octavia Ionescu

^4,5

,

Ciprian Cirimbei

^4,5,

Diana Loreta Paun

^6,7,

Andreea Jercan

⁸,

Sorina Nicoleta Badelita

⁸

and

Daniel Coriu

^8,9

¹

Nuclear Medicine Department, University of Medicine and Pharmacy “Carol Davila”, 050474 Bucharest, Romania

²

Nuclear Medicine Department, Institute of Oncology “Prof. Dr. Alexandru Trestioreanu”, 022328 Bucharest, Romania

³

Carcinogenesis and Molecular Biology Department, Institute of Oncology “Prof. Dr. Alexandru Trestioreanu”, 022328 Bucharest, Romania

⁴

General Surgery Department 10, “Carol Davila” University of Medicine and Pharmacy, 050474 Bucharest, Romania

⁵

General Surgery and Surgical Oncology Department I, Bucharest Institute of Oncology “Al. Trestioreanu”, 022328 Bucharest, Romania

⁶

Endocrinology Department, University of Medicine and Pharmacy “Carol Davila”, 050474 Bucharest, Romania

⁷

Endocrinology Department, National Institute of Endocrinology “C.I. Parhon”, 011863 Bucharest, Romania

⁸

Hematology Department, Fundeni Clinical Institute, 022322 Bucharest, Romania

⁹

Hematology Department, University of Medicine and Pharmacy “Carol Davila”, 050474 Bucharest, Romania

^*

Authors to whom correspondence should be addressed.

Diagnostics 2025, 15(4), 482; https://doi.org/10.3390/diagnostics15040482

Submission received: 9 December 2024 / Revised: 1 February 2025 / Accepted: 12 February 2025 / Published: 17 February 2025

(This article belongs to the Special Issue Advances in Cardiovascular Diseases: Diagnosis and Management)

Download

Browse Figures

Versions Notes

Abstract

Background: ATTRv and ATTRwt cardiac amyloidosis (CA) are underrecognized causes of heart failure with preserved left ventricular ejection fraction. The diagnosis of CA remains challenging due to low diagnostic suspicion and clinical overlap with more common diseases. The aim of this study was to use [^99mTc]-PYP SPECT-CT to perform a volumetric evaluation of bone scintigraphy to overcome the limitations of current practices. Methods: A monocentric prospective study was conducted to evaluate a lot of 22 patients with a mean age of 52.86 ± 13.80 years, diagnosed with hereditary cardiac transthyretin amyloidosis (ATTR). Results: Correlations between the quantitative SPECT-CT, clinical data, and morphological parameters were performed, demonstrating moderate to strong correlation of SUVmaxMyocardium/SUVmaxBone to both ECG low voltage and EchoGLS, SUVmaxMyocardium/SUVmaxLiver to myocardial gadolinium kinetics with T1 mapping MRI, diastolic disfunction, sensory–motor polyneuropathy, and EchoGLS, SUVmaxMyocardium/SUVmeanBone with diastolic disfunction and sensory–motor polyneuropathy, as well as SUVmaxMyocardium/SUVmaxSoft tissue to S II, respectively. Conclusions: The moderate to strong correlations among advanced quantitative SPECT-CT metrics and clinical and paraclinical data create the premises to use these parameters for early diagnosis of cardiac ATTR. Further multicentric studies in a larger patient population are needed to validate the newly identified quantitative SPECT-CT parameters.

Keywords: quantitative SPECT-CT; cardiac amyloidosis; ATTR; SUVmax; SUVmean

Share and Cite

MDPI and ACS Style

Gherghe, M.; Mutuleanu, M.-D.; Suta, T.L.; Micu, L.; Stanciu, A.E.; Ionescu, S.-O.; Cirimbei, C.; Paun, D.L.; Jercan, A.; Badelita, S.N.; et al. Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters. Diagnostics 2025, 15, 482. https://doi.org/10.3390/diagnostics15040482

AMA Style

Gherghe M, Mutuleanu M-D, Suta TL, Micu L, Stanciu AE, Ionescu S-O, Cirimbei C, Paun DL, Jercan A, Badelita SN, et al. Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters. Diagnostics. 2025; 15(4):482. https://doi.org/10.3390/diagnostics15040482

Chicago/Turabian Style

Gherghe, Mirela, Mario-Demian Mutuleanu, Tatiana Lucia Suta, Liliana Micu, Adina Elena Stanciu, Sinziana-Octavia Ionescu, Ciprian Cirimbei, Diana Loreta Paun, Andreea Jercan, Sorina Nicoleta Badelita, and et al. 2025. "Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters" Diagnostics 15, no. 4: 482. https://doi.org/10.3390/diagnostics15040482

APA Style

Gherghe, M., Mutuleanu, M.-D., Suta, T. L., Micu, L., Stanciu, A. E., Ionescu, S.-O., Cirimbei, C., Paun, D. L., Jercan, A., Badelita, S. N., & Coriu, D. (2025). Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters. Diagnostics, 15(4), 482. https://doi.org/10.3390/diagnostics15040482

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Future Directions in Quantitative SPECT-CT Evaluation of Cardiac Transthyretin Amyloidosis: Correlation with Clinical and Morphological Parameters

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI